References:

[1]Gorbalenya AE,Baker SC,Baric RS,et al. Severe acute re-spiratory syndrome - related coronavirus:The species and its viruses - a statement of the Coronavirus Study Group [J]. bioRxiv,2020,DOI:10. 1101/2020. 02. 07. 937862.
[2]National Health and Health Commission, State Administra-tion of traditional Chinese medicine. New tr eatment plan for pneumonia with coronary manifestation infection (trialversion 5)[S]. 2020.
[3]国家卫生健康委办公厅,国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第六版)(摘登)[J].健康指南,2020(3):8 -11. [EB/ OL]. (2020 -03 -03)[2020 - 03 - 05 ]. http:/ / www. nhc. gov. cn/ yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ ce3e6945832a438eaae415350a8ce964. pdf.
[4]Zhou P,Yang XL,Wang XG,et al. Discovery of a novelcoronavirus associated with the recent pneumonia outbreakin humans and its potential bat origin[J]. bioRxiv,2020,DOI:10. 1101/2020. 01. 22. 914952.
[5]闵瑞,刘洁,代喆,等. 新型冠状病毒肺炎发病机制及临床研究进展[J]. 中华医院感染学杂志,2020,30(8):1171 -1176.
[6]中华医学会消化病学分会. 新型冠状病毒肺炎消化系统诊疗专家共识[J/ OL] . 中华医学杂志,2020,100(2020 - 03 - 16 ). http:/ / rs. yiigle. com/ yufabiao/1184864. htm.
[7]Xu Z,Shi L,Wang YJ,et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J].The Lancet. Respiratory Medicine,2020,8(4):420 -422.
[8]褚扬,周王谊,吴江,等. 新型冠状病毒肺炎治疗中应关注肝损伤及防治中药概述[J]. 世界中医药,2020,15(2):129 -133. .
[9]余爱荣,范星,赵燕,等. 洛匹那韦/ 利托那韦联合其他抗病毒药治疗新型冠状病毒肺炎的疗效与安全性[J].医药导报,2020,39(5):628 -632.
[10]胡利琳,王炜珺,朱清静,等. 新型冠状病毒感染肺炎相关肝脏损伤:病因分析及治疗策略[J]. 中华肝脏病杂志,2020,28(2):97 -99.
[11]Ling Y,Xu SB,Lin YX,et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilita-tion patients[J]. Chinese Medical Journal,2020,133(9):1039 -1043.
[12]谢铱子,纪树亮,钟彩婷,等. 藿朴夏苓汤治疗新型冠状病毒肺炎的网络药理学分子机制研究[J]. 中药材,[2020 -03 -20].http:/ / kns. cnki. net/ kcms/ detail/44. 1286. R. 20200320.1105. 002. html
[13]常丽萍. 温病湿热证大鼠模型复制及加味藿朴夏苓汤作用机制的探讨[D]. 南宁:广西医科大学,2011.